Basilea Pharmaceutica to File Application for Marketing Authorization of Ceftobiprole for the Treatment of Pneumonia

Published: Jan 05, 2012

BASEL, SWITZERLAND--(Marketwire - January 05, 2012) -

Basilea Pharmaceutica AG /

Basilea to file application for marketing authorization of ceftobiprole for the treatment of pneumonia

Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

Basel, Switzerland, January 5, 2012 - Basilea Pharmaceutica Ltd. (SIX: BSLN) today announced that it will apply in the second half of 2012 for approval of its antibiotic ceftobiprole in Europe. In addition, reporting of topline data for the alitretinoin U.S. phase III study for chronic refractory hand eczema will occur in the first quarter of this year. Basilea thus has the potential for two regulatory submissions in 2012.

Basilea has completed investigator site audits of two international double- blind randomized controlled phase III studies of ceftobiprole for the treatment of severe community-acquired and hospital-acquired pneumonia. The audits included 26 investigator sites, covering more than one third of patients of both trials. On the basis of these audits and following health authority feedback on potential filing strategies, Basilea has decided to apply in the second half of 2012 for the approval of ceftobiprole in Europe for pneumonia treated in the hospital setting.

CEO Dr. Anthony Man commented: "Ceftobiprole is a unique antibiotic that has the potential to provide broad antibacterial coverage in the treatment of patients with severe and life-threatening pneumonia. Based on independent site audits and the robustness of the trial data we plan to file an application for marketing approval for severe pneumonia treated in the hospital setting. We target filing in Europe in the second half of 2012. We will finalize our filing plans for the U.S. upon additional discussions with the FDA."

All patients of the alitretinoin U.S. phase III HANDEL study have completed the blinded six-month follow-up period after end of treatment. The company is preparing the database lock and subsequent unblinding of data. The U.S. program includes comprehensive safety assessments such as bone mineral density measurements, audiological, ophthalmological and psychiatric assessments. Following detailed analyses of this study, Basilea plans to discuss with the FDA the design of a risk evaluation and mitigation strategies (REMS) program to support a potential New Drug Application (NDA) filing.

Dr. Man stated: "We expect topline data from this comprehensive study in the first quarter. We plan to file by the end of 2012 after bone mineral density data is available at mid-year and we have had a subsequent pre-NDA meeting with the FDA."

Conference call

Basilea Pharmaceutica Ltd. invites you to participate in a conference call on Thursday, January 5, 2012, 4 p.m. (CET), during which the company will discuss today's press release.

Dial-in numbers are:

+41 (0) 91 610 56 00 (Europe and ROW)

+1 (1) 866 291 4166 (USA)

+44 (0) 203 059 5862 (UK)

A playback will be available 1 hour after the conference call until Monday, January 9, 2012, 6 p.m. (CET). Participants requesting a digital playback may dial:

+41 (0) 91 612 4330 (Europe and ROW)

+1 (1) 866 416 2558 (USA)

+44 (0) 207 108 6233 (UK)

and will be asked to enter the ID 13427 followed by the # sign.

About ceftobiprole

Inappropriate initial antimicrobial therapy is associated with excess mortality in patients with serious bacterial infections including severe pneumonia treated in the hospital. In order to provide appropriate initial therapy, empiric treatment should include antibiotics covering methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.

Ceftobiprole is an investigational new broad-spectrum cephalosporin antibiotic for the potential first-line (empiric) treatment of severe multi-drug resistant bacterial infections. Available data demonstrate activity against a wide range of Gram-positive bacteria, including the MRSA 'superbug' as well as clinically- relevant Gram-negative bacteria such as Pseudomonas spp. and Acinetobacter spp. Ceftobiprole has been tested in a large clinical program including two phase III studies each in the indications of pneumonia (patients hospitalized with community-acquired pneumonia and patients with hospital-acquired pneumonia) and complicated skin and skin structure infections. In total, more than 3000 patients were enrolled in these studies.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Basilea Pharmaceutica International Ltd.'s fully integrated research and development operations are focused on antibiotics, antifungals and oncology drugs, as well as on the development of dermatology drugs, targeting the medical challenge of resistance and non-response to current treatment options in the hospital and specialty care setting.


This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward- looking statements contained herein as a result of new information, future events or otherwise.

This press release can be downloaded from

Press release (PDF):

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Basilea Pharmaceutica AG via Thomson Reuters ONE


For further information, please contact:

Media Relations
Peer Nils Schroder, Ph.D.
Head Public Relations & Corporate Communications
+41 61 606 1102
Email Contact

Investor Relations
Barbara Zink, Ph.D., MBA
Head Corporate Development
+41 61 606 1233
Email Contact

Back to news